PT - JOURNAL ARTICLE AU - Barbara Iadarola AU - Denise Lavezzari AU - Alessandra Modi AU - Chiara Degli Esposti AU - Cristina Beltrami AU - Marzia Rossato AU - Valentina Zaro AU - Ettore Napione AU - Leonardo Latella AU - Martina Lari AU - David Caramelli AU - Alessandro Salviati AU - Massimo Delledonne TI - Whole-exome sequencing of the mummified remains of Cangrande della Scala (1291–1329 CE) indicates the first known case of late-onset Pompe disease AID - 10.1101/2021.06.08.21258201 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.08.21258201 4099 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258201.short 4100 - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258201.full AB - Mummified remains of relevant historical figures are nowadays an important source of information to retrace data concerning their private life and health, especially when historical archives are not available. Next-generation-sequencing was proved to be a valuable tool to unravel the characteristics of these individuals through their genetic heritage. Using the strictest criteria currently available for the validation of ancient DNA sequences, whole-genome and whole-exome sequencing were generated from the mummy remains of an Italian nobleman died almost 700 years ago, Cangrande della Scala. While its genome sequencing could not yield sufficient coverage for in depth investigation, exome sequencing could overcome the limitations of this approach to achieve significantly high coverage on coding regions, thus allowing to perform the first extensive exome analysis of a mummy genome. Similar to a standard “clinical exome analysis” conducted on modern DNA, an in-depth variant annotation, high-quality filtering and interpretation was performed, leading to the identification of a genotype associated with late-onset Pompe disease (glycogen storage disease type II). This genetic diagnosis was concordant with the limited clinical history available for Cangrande della Scala, who likely represents the earliest known case of this autosomal recessive metabolic disorder.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This investigation was conducted by the University of Verona and the University of Florence in collaboration with the Natural History Museum of Verona. This study was approved within the Project JPVR18NCXA. Institutional review boards: Joint project evaluation committeee of University of Verona. Decision made: givenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe WES variants data are available for download from our public repository using the provided link (VCF file with associated BED files of callable regions). http://ddlab.sci.univr.it/files/Cangrande/Cangrande.tar.gz